New Chromsystems Product for Antiepileptic Drugs Testing

Chromsystems announces the launch and immediate availability of the MassTox® TDM Series A Parameter Set Antiepileptic Drugs XT2 in Serum/Plasma – All-in-One Method. The updated parameter set extends the MassTox® TDM portfolio, helping laboratories meet clinical needs and regulatory requirements in therapeutic drug monitoring.

The assay measures 28 analytes in a single chromatographic run, enabling efficient sample processing and consistent turnaround times. The panel includes cenobamate, a recently approved antiepileptic drug, providing access to clinically relevant data for emerging therapies. Each analyte is paired with its own internal standard. The assay is fully IVDR certified, ensuring alignment with current regulatory standards.

Key benefits:

• Parameter menu including cenobamate for broader clinical information
• Individual internal standards for measurement control
• Single chromatographic run for streamlined workflows
• Integrated within the MassTox® TDM Series A portfolio

The MassTox® TDM Series A Parameter Set XT2 supports laboratories in generating results efficiently while maintaining regulatory compliance.

Read more: www.chromsystems.com/aed